Graphex Group, together with its wholly owned U.S. subsidiary, Graphex Technologies, LLC (NYSE American: GRFX), commented on the recent news out of China regarding new controls on graphite exports, re-emphasizing the Company’s strategic approach to deliver the necessary anode material to meet the needs of North American automakers and battery manufacturers for Lithium-ion batteries required for EVs, energy storage, and other advanced use cases.

Genius Group (NYSE American: GNS), a leading entrepreneur edtech and education group, announced that following the recent announcement that Genius Group’s CEO, Roger James Hamilton, is providing the company with up to $4 million in funding, the Company has received notice of additional funding from executives within Genius Group. Senior executives and shareholders in Genius Group, which include founders of a number of the companies acquired by Genius Group in 2022 and 2023, together with other senior executives of the Company, are providing additional funding amounting to approximately $2 million in the form of both interest free loans and earnings converted to equity.

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), announced the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on the path forward for Oxylanthanum Carbonate (OLC) and on the overall package requirements to file a New Drug Application. In the Type C meeting, plans were confirmed with the FDA for the pivotal clinical trial. The Agency agrees with the Company's study design of 60 participants to be evaluated for 4 weeks on OLC once participants are titrated to clinically effective doses. The study is designed to evaluate tolerability and the event rate for discontinuation; therefore, there is no statistical analysis required to demonstrate efficacy. No other clinical study is required. We believe that results from this pivotal trial will enhance our safety data package from preclinical studies, and the efficacy data is referenced with Unicycive’s previously disclosed bioequivalence study.

QYOU Media (OTCQB: QYOUF), a company operating in India and the United States producing and distributing content created by social media stars and digital content creators, announced a significant expansion of its Connected TV distribution for QPlay+ and its featured channels via a partnership with Coolita, a leading global smart TV+OS brand. As a part of this strategic alliance, Coolita users in India and across the globe, through their wide range of smart TV sets including COOCA, METZ, Panasonic, Croma, Thomson and others, along with their operating software Coolita, will have simple access to stream QYOU Media India's growing portfolio of FAST channels - including The Q, The Q Kahaniyan, Q GameX, Sadhguru TV, and Bollywood Hungama Live on a free ad supported basis.